We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $524M
1-Year Est. Return 164.42%
This Fund
S&P 500
This Quarter Est. Return
+11.29%
1 Year Est. Return
+164.42%
3 Year Est. Return
+313.04%
5 Year Est. Return
+302.83%
10 Year Est. Return
+4,361.99%
AUM
$244M
AUM Growth
+$29.9M
Cap. Flow
+$6.34M
Cap. Flow %
2.6%
Top 10 Hldgs %
46.31%
Holding
78
New
4
Increased
21
Reduced
24
Closed
3

Top Buys

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$3.4M
2
FOMX
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
+$2.69M
3
BLUE
bluebird bio
BLUE
+$2.63M
4
ZGNX
Zogenix, Inc.
ZGNX
+$2.06M
5
LOXO
Loxo Oncology, Inc
LOXO
+$1.85M

Top Sells

Rank Stock Value
1
DXCM icon
DexCom
DXCM
+$2.23M
2
NERV icon
Minerva Neurosciences
NERV
+$977K
3
LMNX
Luminex Corp
LMNX
+$945K
4
LRMR icon
Larimar Therapeutics
LRMR
+$784K
5
ATRC icon
AtriCure
ATRC
+$684K

Sector Composition

Rank Sector Weight
1 Healthcare 95.93%
2 Miscellaneous 3.62%
3 Financials 0.45%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LOXO
1
DELISTED
Loxo Oncology, Inc
LOXO
$29M 11.9%
169,675
+11,000
+7% +$1.85M
STXS icon
2
Stereotaxis
STXS
$145M
$16.6M 6.8%
13,680,554
– –
SAGE
3
DELISTED
Sage Therapeutics
SAGE
$14M 5.76%
99,306
+3,306
+3% +$510K
ATRC icon
4
AtriCure
ATRC
$2.47B
$10.3M 4.23%
293,729
-21,616
-7% -$684K
NXTM
5
DELISTED
NxStage Medical Inc.
NXTM
$8.54M 3.51%
306,119
– –
AERI
6
DELISTED
Aerie Pharmaceuticals
AERI
$8.17M 3.36%
132,770
+1,000
+0.8% +$64.3K
BPMC
7
DELISTED
Blueprint Medicines
BPMC
$7.24M 2.97%
92,691
– –
ZGNX
8
DELISTED
Zogenix, Inc.
ZGNX
$6.86M 2.82%
138,264
+40,500
+41% +$2.06M
ALDR
9
DELISTED
Alder Biopharmaceuticals
ALDR
$6.59M 2.71%
396,013
– –
AKBA icon
10
Akebia Therapeutics
AKBA
$243M
$5.53M 2.27%
625,738
+15,000
+2% +$134K
ASND icon
11
Ascendis Pharma A/S
ASND
$16.3B
$5.47M 2.25%
77,242
+3,497
+5% +$241K
DXCM icon
12
DexCom
DXCM
$34.3B
$5.29M 2.17%
148,000
-72,000
-33% -$2.23M
NBIX icon
13
Neurocrine Biosciences
NBIX
$15.7B
$5.04M 2.07%
41,008
-4,500
-10% -$511K
PRQR icon
14
ProQR Therapeutics
PRQR
$323M
$5.04M 2.07%
260,336
+88,985
+52% +$946K
BCRX icon
15
BioCryst Pharmaceuticals
BCRX
$2.51B
$4.97M 2.04%
652,086
+47,434
+8% +$319K
ARGX icon
16
argenx
ARGX
$64B
$4.88M 2%
64,300
+38,351
+148% +$3.4M
FOMX
17
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$4.63M 1.9%
808,000
+470,000
+139% +$2.69M
ARNA
18
DELISTED
Arena Pharmaceuticals Inc
ARNA
$4.54M 1.86%
98,547
+3,305
+3% +$134K
LKFT
19
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.89B
$4.45M 1.83%
39,609
-1,000
-2% -$106K
KURA icon
20
Kura Oncology
KURA
$1.13B
$4.21M 1.73%
240,500
+1,000
+0.4% +$19.2K
LMNX
21
DELISTED
Luminex Corp
LMNX
$4.2M 1.72%
138,391
-31,500
-19% -$945K
IMMU
22
DELISTED
Immunomedics Inc
IMMU
$3.71M 1.52%
178,000
-5,000
-3% -$118K
CBAY
23
DELISTED
Cymabay Therapeutics
CBAY
$3.26M 1.34%
294,511
– –
IBB icon
24
iShares Biotechnology ETF
IBB
$10.5B
$3.18M 1.31%
26,100
– –
XENE icon
25
Xenon Pharmaceuticals
XENE
$5.81B
$3.14M 1.29%
237,683
-56,679
-19% -$657K
1
2 3

Similar funds

4WM
49 Wealth Management Austin, Texas $524M AUM 16.59% 1-Year Est. Return
BB
Berkshire Bank Pittsfield, Massachusetts $524M AUM 21.97% 1-Year Est. Return
A
Alongside Austin, Texas $525M AUM
HW
Hedeker Wealth Lincolnshire, Illinois $524M AUM 36.83% 1-Year Est. Return
DAM
Decagon Asset Management London, United Kingdom $525M AUM 50.51% 1-Year Est. Return
SDWIA
Schwarz Dygos Wheeler Investment Advisors Minneapolis, Minnesota $524M AUM 25.1% 1-Year Est. Return
SCA
Stieven Capital Advisors St. Louis, Missouri $524M AUM 29.72% 1-Year Est. Return
BHPW
Beverly Hills Private Wealth Beverly Hills, California $525M AUM 24.1% 1-Year Est. Return

DAFNA Capital Management's Q3 2018 Portfolio in Review

As of Q3 2018, DAFNA Capital Management held 78 positions worth $244M, up 14% from $214M the previous quarter. Its ten largest holdings account for 46% of the portfolio.

DAFNA Capital Management's Q3 2018 filing shows 4 new, 21 increased, 24 reduced and 3 closed positions. Its largest new stake was Spero Therapeutics: 70,000 shares worth $736K. The largest sale was DexCom, an estimated $2.23M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 94% a quarter earlier, followed by Miscellaneous and Financials.

  • DAFNA Capital Management's largest Q3 2018 buy was Spero Therapeutics: 70,000 shares worth $736K.
  • DAFNA Capital Management added most to argenx in Q3 2018, an estimated $3.4M increase.
  • DAFNA Capital Management's biggest Q3 2018 reduction was DexCom, cutting an estimated $2.23M.
  • DAFNA Capital Management fully exited Galmed Pharmaceuticals in Q3 2018, selling an estimated $595K.
  • DAFNA Capital Management's ten largest holdings make up 46% of its $244M portfolio in Q3 2018.
  • DAFNA Capital Management opened 4 new positions and closed 3 in Q3 2018.
  • DAFNA Capital Management's portfolio value rose 14% quarter-over-quarter to $244M.

Based on DAFNA Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.